Neurogene (NGNE) Retained Earnings (2013 - 2026)
Neurogene (NGNE) posted Retained Earnings of $621.4 million for Q1 2026, up 0.62% on a QoQ basis from $617.5 million in Q4 2025, and up 318.07% year-over-year from $148.6 million in Q1 2025.
Neurogene (NGNE) Retained Earnings (2013 - 2026) Analysis & Trends
Neurogene's Retained Earnings history runs 14 years deep, the most recent figure standing at $621.4 million for Q1 2026.
- Quarterly Retained Earnings rose 318.07% year-over-year to $621.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $621.4 million (up 318.07% YoY) and the FY2025 annual result came in at $617.5 million, up 7.83% from the prior year.
- Retained Earnings was $621.4 million for Q1 2026 at Neurogene, up from $617.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at $621.4 million in Q1 2026 and bottomed at -$327.9 million in Q3 2025.
- A 5-year average of $164.6 million and a median of $5.1 million in 2022 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 759729.17% in 2023, while the deepest fall reached 3771.13% in 2023.
- Neurogene's Retained Earnings stood at $5.1 million in 2022, then tumbled by 3771.13% to -$187.2 million in 2023, then surged by 405.99% to $572.7 million in 2024, then climbed by 7.83% to $617.5 million in 2025, then gained by 0.62% to $621.4 million in 2026.
- Business Quant data shows NGNE's Retained Earnings at $621.4 million in Q1 2026, $617.5 million in Q4 2025, and -$327.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Neurogene | 772.67 Mn | 772.67 Mn | - | 621.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 621.37 Mn |
| Dec 31, 2025 | 617.54 Mn |
| Sep 30, 2025 | -327.91 Mn |
| Jun 30, 2025 | -307.00 Mn |
| Mar 31, 2025 | -284.95 Mn |
| Dec 31, 2024 | 572.67 Mn |
| Sep 30, 2024 | -242.80 Mn |
| Jun 30, 2024 | -222.60 Mn |
| Mar 31, 2024 | 374.85 Mn |
| Dec 31, 2023 | -187.15 Mn |
| Sep 30, 2023 | 547.11 Mn |
| Jun 30, 2023 | 546.93 Mn |
| Mar 31, 2023 | 546.60 Mn |
| Dec 31, 2022 | 5.10 Mn |
| Sep 30, 2022 | -92,000.00 |
| Jun 30, 2022 | -72,000.00 |
| Mar 31, 2022 | 538.94 Mn |
| Dec 31, 2021 | 536.36 Mn |
| Sep 30, 2021 | -378.33 Mn |
| Jun 30, 2021 | 529.96 Mn |